Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Sun Pharmaceutical Industries Ltd. reported a 10.5% YoY increase in Q3 FY25 sales, reaching INR 134,369 million, driven by underlying business growth and milestone income in the Rest of World (ROW) segment. Excluding milestones, sales grew by 8.9%.
- Global Specialty sales demonstrated robust growth, increasing by 24.8% YoY to reach US$ 370 million, offsetting declines in the U.S. generics business.
- India formulations sales grew by 13.8% YoY, reaching INR 43,004 million, driven by volume growth and new product launches. Sun Pharma maintains its leading position in the Indian pharmaceutical market with an 8.2% market share.
- Emerging markets revenue increased by 10.1% YoY to US$ 277 million, with underlying growth in constant currency terms at 14%.
- R&D expenditure for Q3 FY25 was INR 8,450 million, representing 6.3% of sales. Specialty R&D constituted 41% of the total R&D spend. Full-year R&D spending is now expected to be below 7% of sales due to delays in clinical trials.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.